Lenivia 1.5 mg Solution for Injection for Dogs (2x 1ml vial)

Lenivia is a caninised monoclonal antibody (mAb) that targets Nerve Growth Factor (NGF), a key protein involved in pain signalling and inflammation. By neutralising NGF, izenivetmab helps to interrupt the pain signals, providing effective and targeted relief for dogs suffering from osteoarthritis.

As a responsible dog owner, seeing your pet in discomfort can be distressing. Lenivia 1.5 mg Solution for Injection for Dogs offers a monthly injection solution designed to improve your dog's comfort and restore their desire to move and play. This can lead to increased activity, better interactions, and an overall improvement in their well-being.

Why choose Lenivia for your dog?

• Targeted Pain Relief: Izenivetmab works directly on the pain pathway by binding to NGF.
• Improved Mobility: By reducing pain, dogs can experience better movement and flexibility.
• Enhanced Quality of Life: Helping your dog feel more comfortable allows them to enjoy daily activities again.
• Convenient Monthly Dosing: A simple once-a-month subcutaneous injection, administered by a veterinary professional, supports consistent pain management.

At Weldricks Pharmacy, we understand the importance of accessible and reliable pet pharmacy products. Explore our range of Dog Pharmacy options and Vet Products to support your dog's health.

Always follow your veterinary surgeon's instructions precisely regarding the dosage and administration of Lenivia 1.5 mg Solution for Injection for Dogs.

• Route of Administration: Administer subcutaneously (under the skin).

It is crucial to be aware of the following warnings and precautions when using Lenivia 1.5 mg Solution for Injection for Dogs:

Contraindications:

• Do not use in dogs younger than 12 months of age.
• Do not use in pregnant or lactating bitches.
• Do not use in breeding animals.
• Do not use if there is a known hypersensitivity to izenivetmab or any of the excipients.

Special Warnings:

• This product may lead to the development of anti-drug antibodies, which could reduce its effectiveness. If your dog's condition does not improve, discuss alternative treatments with your vet.
• Lenivia contains izenivetmab, a canine monoclonal antibody (mAb). Studies with similar anti-NGF antibodies have shown potential effects on the female reproductive system and foetal development.
• The safety and efficacy in puppies under 12 months, or in dogs with kidney or liver disease, have not been fully established. Use in these cases should be carefully considered by your vet based on a benefit-risk assessment.

Special Precautions for Use in Animals:

• A small percentage of dogs may not respond fully to izenivetmab. Your veterinary surgeon should monitor your dog monthly for changes in osteoarthritis pain.
• Safety data beyond 6 months of treatment has not been evaluated.

Special Precautions for Persons Administering the Product:

• Accidental self-injection may cause hypersensitivity reactions, including anaphylaxis. Repeated accidental self-injection increases this risk.
• Pregnant women, women attempting to conceive, or nursing women should exercise extreme caution to prevent accidental self-injection.
• In case of accidental self-injection, seek immediate medical advice and show the package leaflet or label to the doctor.

Adverse Reactions:

Commonly observed side effects in clinical studies include:

• Slight redness, swelling, and heat at the injection site.
• Nausea, diarrhoea, vomiting.
• Increased thirst.
• Lethargy.

If you notice any serious effects or other effects not mentioned, please inform your veterinary surgeon.

Each ml of Lenivia 1.5 mg Solution for Injection for Dogs contains:

• Active substance: Izenivetmab 1.5 mg/ml
• Excipients:
  • Disodium phosphate heptahydrate
  • Sodium dihydrogen phosphate dihydrate
  • Sodium chloride
  • Polysorbate 80
  • Water for injections